David Day

Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective

ABSTRACT Objective: To evaluate the cost of lost productivity in the workplace due to allergic rhinitis compared to other selected medical conditions from an employer perspective. Setting and participants: A total of 8267 US employees at 47 employer locations who volunteered to participate in health/wellness screenings. Measurements: The Work Productivity Short Inventory was used to assess the impact of a predefined group of health conditions on workplace productivity for the previous 12 months. Both absenteeism and presenteeism (lost productivity while at work) were recorded. Costs were calculated using a standard hourly wage. Results: Allergic rhinitis was the most prevalent of the selected conditions; 55% of employees reported experiencing allergic rhinitis symptoms for an average of 52.5 days, were absent 3.6 days per year due to the condition, and were unproductive 2.3 h per workday when experiencing symptoms. The mean total productivity (absenteeism + presenteeism) losses per employee per year were US

Relationship between obesity and cardiovascular risk factors: findings from a multi-state screening project in the United States*

593 for allergic rhinitis,

A new tool for predicting erectile dysfunction

518 for high stress,

Cost advantage of voriconazole over amphotericin b deoxycholate for primary treatment of invasive aspergillosis

277 for migraine,

Population-based screening with the Coronary Heart Disease Risk Factor Calculator.

273 for depression,

Use of Pharmacy Claims Databases to Determine Rates of Medication Adherence

269 for arthritis/rheumatism,

Computer-assisted evaluation of antibiotic regimen coverage and cost.

248 for anxiety disorder,

Predicting the Risk for Gastrointestinal Toxicity in Patients Taking NSAIDs: The Gastrointestinal Toxicity Survey

181 for respiratory infections,

AIP: A proposed mechanism for evaluating adherence improvement initiatives

105 for hypertension or high blood pressure,

Therapy Cost 2000: a computer model for pharmacoeconomic analysis

95 for diabetes,